BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10227448)

  • 1. Amifostine as a protector against cisplatin-induced toxicity in nude mice.
    Johnsson A; Wennerberg J
    Acta Oncol; 1999; 38(2):247-53. PubMed ID: 10227448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.
    Bergström P; Johnsson A; Bergenheim T; Henriksson R
    J Neurooncol; 1999 Mar; 42(1):13-21. PubMed ID: 10360475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
    Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
    Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
    Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
    Eur J Cancer; 1998 Feb; 34(3):412-6. PubMed ID: 9640232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the protective effects of amifostine against cisplatin-induced toxicity.
    Hussain AE; Blakley BW; Nicolas M; Balderston J
    J Otolaryngol; 2003 Oct; 32(5):294-7. PubMed ID: 14974858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct amifostine effect on renal tubule cells in rats.
    Weichert-Jacobsen KJ; Bannowski A; Küppers F; Loch T; Stöckle M
    Cancer Res; 1999 Jul; 59(14):3451-3. PubMed ID: 10416609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine protective effect on cisplatin-treated rat testis.
    Lirdi LC; Stumpp T; Sasso-Cerri E; Miraglia SM
    Anat Rec (Hoboken); 2008 Jul; 291(7):797-808. PubMed ID: 18543292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of Ginkgo flavonoids, amifostine, and leuprorelin against platinum-induced ovarian impairment in rats.
    Chang Z; Wang HL; Du H
    Genet Mol Res; 2014 Jul; 13(3):5276-84. PubMed ID: 25078583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer.
    Dunn TA; Schmoll HJ; Grünwald V; Bokemeyer C; Casper J
    Anticancer Drugs; 1996 Sep; 7(7):795-9. PubMed ID: 8949993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metoclopramide as a modulator of cisplatin: effects on pharmacokinetcs and cisplatin-DNA adducts in tumor and normal tissue.
    Johnsson A; Kjellén E; Wennerberg J; Pero R
    Anticancer Drugs; 1996 Jun; 7(4):483-8. PubMed ID: 8826617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
    Korst AE; van der Sterre ML; Gall HE; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
    Clin Cancer Res; 1998 Feb; 4(2):331-6. PubMed ID: 9516919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts.
    Johnsson A; Strand C; Los G
    Cancer Chemother Pharmacol; 1999; 43(4):348-52. PubMed ID: 10071988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil.
    Peters GJ; van der Wilt CL; Gyergyay F; van Laar JA; Treskes M; van der Vijgh WJ; Pinedo HM
    Int J Radiat Oncol Biol Phys; 1992; 22(4):785-9. PubMed ID: 1312075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of radioactive cisplatin (191Pt) on nude mice.
    Areberg J; Wennerberg J; Johnsson A; Norrgren K; Mattsson S
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):827-32. PubMed ID: 11172966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.
    Verstappen CC; Geldof AA; Postma TJ; Heimans JJ
    J Neurooncol; 1999 Aug; 44(1):1-5. PubMed ID: 10582662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S; Chewaskulyong B
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
    van der Vijgh WJ; Korst AE
    Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.